三鑫醫療(300453.SZ):2019年淨利預增30%-50%
格隆匯1月15日丨三鑫醫療(300453.SZ)披露2019年度業績預告,公司預計2019年1-12月實現歸屬於上市公司股東的淨利潤5350萬元-6173萬元,同比增長30%-50%。業績變動原因説明:
1、報告期內,公司繼續加大市場開拓力度,主營業務收入特別是血液淨化系列產品的銷售收入較上年同期增幅較大,保持了連續快速增長。
2、公司實施精益生產,報告期內進一步提升了生產管理效率,且部分原材料價格較上年同期有所下降,報告期內綜合毛利率有所上升。
3、隨着全資子公司雲南三鑫業務規模的不斷擴大、生產管理效率的提高、成本控制的加強,雲南三鑫報告期內扭虧為盈。
4、報告期內,非同一控制下的控股子公司寧波菲拉爾醫療用品有限公司和成都威力生生物科技有限公司先後納入合併報表範圍,對公司報告期內淨利潤有積極貢獻。
5、報告期內,公司收到的政府補助較上年同期有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.